Literature DB >> 27859635

Abaloparatide Is an Anabolic, but Does It Spare Resorption?

T John Martin1,2, Ego Seeman3,4.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27859635     DOI： 10.1002/jbmr.3042

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  5 in total

Review 1.  Side effects of drugs for osteoporosis and metastatic bone disease.

Authors:  Michael Kriegbaum Skjødt; Morten Frost; Bo Abrahamsen
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

2.  Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis.

Authors:  Tae-Keun Ahn; Kyoung-Tae Kim; Hari Prasad Joshi; Kwang Hwan Park; Jae Won Kyung; Un-Yong Choi; Seil Sohn; Seung-Hun Sheen; Dong-Eun Shin; Soo-Hong Lee; In-Bo Han
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

Review 3.  Advances and Unmet Needs in the Therapeutics of Bone Fragility.

Authors:  Sabashini K Ramchand; Ego Seeman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-06       Impact factor: 5.555

4.  Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.

Authors:  E V McCloskey; L A Fitzpatrick; M-Y Hu; G Williams; J A Kanis
Journal:  Arch Osteoporos       Date:  2019-02-05       Impact factor: 2.617

5.  The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.

Authors:  Mikkel Bo Brent; Jesper Skovhus Thomsen; Annemarie Brüel
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.